Deborah Birx, MD
Former White House Coronavirus Task Force Coordinator
Gianrico Farrugia, MD
President & CEO
Joshua Denny, MD, MS
All of Us Research Program
National Institutes of Health
Creating the Future of Health Care
Gianrico Farrugia, M.D., president and CEO of Mayo Clinic, leads one of the largest not-for-profit, academic health systems in the U.S., with 70,000 staff and $14 billion in annual revenue. Mayo Clinic focuses on patients with serious or complex illnesses, caring for more than 1.2 million unique patients each year from all 50 states and nearly 140 countries. Prior to his current appointment, Dr. Farrugia served as CEO of Mayo Clinic in Florida, led Mayo Clinic’s Center for Individualized Medicine, and co-founded Mayo Clinic’s Center for Innovation. He is a member of the Mayo Clinic Board of Trustees and Mayo Clinic Board of Governors, and is a professor of medicine and physiology, Mayo Clinic College of Medicine and Science. Dr. Farrugia has been a Mayo Clinic physician for 30 years. He is jointly appointed in the Division of Gastroenterology and Hepatology, Department of Internal Medicine, and the Department of Physiology and Biomedical Engineering. He is the co-author of “Think Big, Start Small, Move Fast: A Blueprint for Transformation from the Mayo Clinic Center for Innovation,” a book highlighting the need for change in the delivery of health care. In addition, he has published more than 300 articles on genomics and the treatment of disorders of gastrointestinal motility. Dr. Farrugia will discuss Mayo Clinic’s approaches in the future of health care and artificial-intelligence-driven innovation.
Healthcare 3.0: How Technology is Driving the Transition to Prosumers, Platforms and Outsurance
Precision Obesity Therapy
AI, Imaging and Precision Medicine
As associate chair of Research for Mayo Clinic Radiology Informatics Division, Brad Erickson, M.D. Ph.D., uses artificial intelligence to diagnose and treat diseases, including scanning MRI images and identifying molecular markers for patients with glioma. Dr. Erickson, who received his medical degrees at Mayo Clinic, has been awarded multiple grants during his 20 years in neuroradiology, including NIH awards for multiple sclerosis, brain tumors, polycystic kidney disease and medical image processing. In addition, he serves as chair on the board of directors for the American Board of Imaging Informatics, he’s a board member of Integrating the Healthcare Enterprise USA, and he recently served as president of the Society of Imaging Informatics in Medicine. Dr. Erickson also holds several patents and has been involved in three startup companies.
Omics Data Platform
John D. Halamka, M.D., M.S., president of Mayo Clinic Platform, leads a portfolio of platform businesses focused on transforming health care by leveraging artificial intelligence, connected health care devices and a network of trusted partners. Trained in emergency medicine and medical informatics, Dr. Halamka has been developing and implementing health care information strategy and policy for more than 25 years. Prior to his appointment at Mayo Clinic, Dr. Halamka was executive director of the Health Technology Exploration Center for Beth Israel Lahey Health in Massachusetts, where he oversaw digital health relationships with industry, academia and government worldwide. He had previously served as chief information officer at Beth Israel Deaconess Medical Center for more than 20 years. Dr. Halamka has written a dozen books about technology-related issues, hundreds of articles and thousands of posts on the Geekdoctor blog. He also runs Unity Farm in Sherborn, Massachusetts, which includes 250 animals, 30 acres of agricultural production, a cidery and winery.
Genetically Engineered Cellular Therapy
Helen Heslop, M.D. DSc, is professor of Medicine and Pediatrics at Baylor College of Medicine, and director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. As a physician scientist, Dr. Heslop is engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She has extensive experience in developing and conducting cell and gene therapy studies and currently holds 23 Investigational New Drugs (IND). In addition, she serves as principal investigator on several peer-reviewed research programs, including an NCI-funded project grant (Enhancing T-Cell Therapy of Cancer), a Leukemia and Lymphoma Society Specialized Center of Research award (Immunotherapy of Lymphoma), the Meg Vosberg Stand Up to Cancer Dream Team in T cell lymphoma, and a SPORE in lymphoma from the National Cancer Institute. She is also the principal investigator on an NHLBI-funded training grant in Cell and Gene Therapy and Chair-elect of the Blood and Marrow Transplant Clinical Trials Network.
Solving the Last Mile: Genomics in Primary Care
Dr. Hulick, M.D., MMSc, is medical director of the Mark R. Neaman Center for Personalized Medicine, and division head for the Center for Medical Genetics at NorthShore University HealthSystem, which applies genetic analysis to prevention, diagnosis and treatment of inherited diseases and disorders. Dr. Hulick also serves as a clinical assistant professor in the Department of Human Genetics at the University of Chicago Pritzker School of Medicine. Previously, he served as an attending physician in medical genetics at Massachusetts General Hospital in Boston, Massachusetts. He has authored or co-authored more than 20 peer reviewed journal articles.
Purna Kashyap, M.B.B.S., is an associate professor of Medicine, Physiology and Biomedical Engineering and the co-program director of the Microbiome program in Mayo Clinic’s Center for Individualized Medicine. He is also a fellow of the American Gastroenterology Association and member of their Center for Gut Microbiome Education and Research, and serves on the council of American Neurogastroenterology and Motility Society. Dr. Kashyap is associate editor of Gut Microbes journal and serves on the editorial board of Neurogastroenterology and Motility and FASEB journal. Dr. Kashyap’s Gut Microbiome Laboratory is interested in understanding the complex interactions between diet, gut microbes, and gastrointestinal function. By combining experimental strategies with bioinformatics analysis, Dr. Kashyap's research team hopes to develop novel microbiota-targeted therapies to treat patients with disorders resulting from altered microbiota function.
WGS Diagnostics-Rare Diseases
Stephen Kingsmore, M.D., DSc., is the founding president and CEO of Rady Children’s Institute for Genomic Medicine (RCIGM) in San Diego, where he leads a multidisciplinary team of scientists, physicians and researchers who are pioneering the use of rapid whole genome sequencing to diagnose rare genetic disorders and guide personalized care for critically-ill newborns and children. Prior to joining RCIGM, Dr. Kingsmore was the founding director of the Center for Pediatric Genomic Medicine at Children’s Mercy Kansas City. He also held the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the University of Missouri-Kansas City School of Medicine. Dr. Kingsmore has also served as President and CEO of the National Center for Genome Resources; COO of Molecular Staging Inc.; Vice President of Research at CuraGen Corporation; founder of GatorGen; and Assistant Professor at the University of Florida’s School of Medicine. In 2019, the National Human Genomic Research Institute cited the publication by the RCIGM team on the use of artificial intelligence to accelerate WGS to diagnose genetic diseases in seriously ill children as among the year’s 10 most significant advances in genomic medicine.
Early Cancer Detection
The Exposome: Measuring Environmental Contributors to Disease on an Omic-Scale
Gary W. Miller, Ph.D. serves as vice dean for Research Strategy and Innovation, and professor of Environmental Health Sciences at the Columbia University Mailman School of Public Health. He is an international leader on the exposome, the environmental equivalent of the genome. He founded the first NIH-funded exposome center in the U.S. (the HERCULES Exposome Research Center at Emory University) and wrote the first book on the topic, The Exposome: A Primer in 2014. Dr. Miller has also helped develop high-resolution mass spectrometry-based methods to provide an omic-scale analysis in human and animal samples. His laboratory studies environmental contributors to neurodegenerative disease, such as Parkinson’s and Alzheimer’s, using C. elegans, transgenic mice, and patient samples. In addition, he is leading the Columbia Exposome Initiative, an effort to incorporate the exposome into clinical and translational research. His new book, The Exposome: a New Paradigm for the Environment and Health, will be published by Elsevier Academic Press in July, 2020.
Genomics’ Next Evolution
Deciphering Infectious Diseases